Presence of anti-GAD in a non-diabetic population of adults; time dynamics and clinical influence: results from the HUNT study | BMJ Open Diabetes Research & Care
N-terminally truncated GAD discriminates progression in GAD antibody positive relatives of patients with type 1 diabetes - Media Centre | EASD
NAA Services for Anti-glutamic Acid Decarboxylase (GAD) - Creative Biolabs
Levels of anti-GAD at beginning of study and after one year in 11 type... | Download Scientific Diagram
Stiff Person Syndrome and Type 1 Diabetes Mellitus: a Case of the Chicken or the Egg? | SpringerLink
Autoantikörperdiagnostik beim Diabetes mellitus
The Role of the Antigen GAD 65 in Diabetes Mellitus Type 1: A Molecular Analysis | IntechOpen
GAD antibodies in neurological disorders — insights and challenges | Nature Reviews Neurology
Neurologic syndromes related to anti-GAD65 | Neurology Neuroimmunology & Neuroinflammation
GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions - Popianna Tsiortou, Harry Alexopoulos, Marinos C. Dalakas, 2021
Fig. Simplified model of mechanism of autoimmunity and beta cell... | Download Scientific Diagram
Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes | SpringerLink
features differentiating between type 1 and type 2 diabetes mellitus - General Practice notebook
Latent autoimmune diabetes in adults (LADA): usefulness of anti-GAD antibody titers and benefit of early insulinization
GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes | NEJM
Diabetes Typ 1 oder Typ 2 – Korrekte Diagnose durch Autoantikörper
Clinical characteristics of type 1 diabetes patients and control... | Download Table
Should anti-glutamic acid decarboxylase antibody levels be determined in new-onset diabetes? - Endocrine Practice
IJMS | Free Full-Text | Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route